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Samir R. Kapadia
One-year outcomes from randomized controlled trials, observational studies, and
pooled analyses have demonstrated the safety and efﬁcacy of percutaneous coronary
intervention (PCI) of the unprotected left main coronary artery (UPLM) when
compared with coronary artery bypass graft surgery (CABG). However, there
remain concerns over the sustainability of PCI with drug-eluting stents (DES) at
longer follow-up. We undertook a systematic review to compare the long-term
outcomes of PCI with DES versus CABG for UPLM stenosis. We found that
PCI with DES is a safe and durable alternative to CABG for the revascularization
of UPLM stenosis in select patients at long-term follow-up.
JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.See additional content in the online version of this issue.EDITORIAL COMMENTWhat Is the Standard of Care for Patients With Left Main Stenosis? 1231John D. Puskas, Emmanuel MossThe Anatomic- and Clinical-Based NERS (New Risk Stratiﬁcation) Score II to Predict
Clinical Outcomes After Stenting Unprotected Left Main Coronary Artery Disease:
Results From a Multicenter, Prospective, Registry Study1233Shao-Liang Chen, Ya-Ling Han, Yao-Jun Zhang, Fei Ye, Hai-Wei Liu, Jun-Jie Zhang, Bo Xu,
Tie-Min Jiang, Yu-Jie Zhou, Shu-Zheng Lv
The NERS (New Risk Stratiﬁcation) score II (including 7 clinical and 9 angio-
graphic variables) was externally compared with the NERS and SYNTAX (Synergy
Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery)
scores in 1,463 patients with unprotected left main coronary artery disease. An
NERS score II 19 demonstrated enhanced sensitivity and speciﬁcity for major
adverse cardiac events (MACE) and was the only independent predictor of
cumulative MACE and stent thrombosis at follow-up.(continued on A-30)
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A-30Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for
Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main
Coronary Artery: The DELTA Registry (Drug-Eluting Stent for Left Main Coronary
Artery Disease): A Multicenter Registry Evaluating Percutaneous Coronary
Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment1242Toru Naganuma, Alaide Chieffo, Emanuele Meliga, Davide Capodanno, Seung-Jung Park,
Yoshinobu Onuma, Marco Valgimigli, Sanda Jegere, Raj R. Makkar, Igor F. Palacios,
Charis Costopoulos, Young-Hak Kim, Piotr P. Buszman, Tarun Chakravarty, Imad Sheiban,
Roxana Mehran, Christoph Naber, Ronan Margey, Arvind Agnihotri, Sebastiano Marra,
Piera Capranzano, Martin B. Leon, Jeffrey W. Moses, Jean Fajadet, Thierry Lefevre,
Marie-Claude Morice, Andrejs Erglis, Corrado Tamburino, Ottavio Alﬁeri, Patrick W. Serruys,
Antonio Colombo
This study compared clinical outcomes after percutaneous coronary intervention
(PCI) with drug-eluting stents for ostial/mid-shaft (n ¼ 482) versus distal bifur-
cation lesions (n ¼ 1,130) in unprotected left main coronary artery. At 1,250 days,
PCI for distal lesions was associated with a higher incidence of major adverse
cardiac events (propensity-score adjusted hazard ratio: 1.48; 95% conﬁdence
interval: 1.16 to 1.89; p ¼ 0.001), largely because of higher target vessel revascu-
larization rates as compared to the rates for ostial/mid-shaft lesions. Propensity-
score adjusted analysis suggested a trend toward higher rates of all-cause death and
the composite endpoint of all-cause death and myocardial infarction in the distal
group. In conclusion, PCI for ostial/mid-shaft lesions is associated with acceptable
outcomes.
See additional content in the online version of this issue.Impact of 3-Dimensional Bifurcation Angle on 5-Year Outcome of Patients After
Percutaneous Coronary Intervention for Left Main Coronary Artery Disease:
A Substudy of the SYNTAX Trial (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery)1250Chrysaﬁos Girasis, Vasim Farooq, Roberto Diletti, Takashi Muramatsu, Christos V. Bourantas,
Yoshinobu Onuma, David R. Holmes, Ted E. Feldman, Marie-Angele Morel,
Gerrit-Anne van Es, Keith D. Dawkins, Marie-Claude Morice, Patrick W. Serruys
This study investigated the impact of left main coronary artery 3-dimensional
bifurcation angle (BA) parameters on 5-year clinical outcomes of patients
randomized to left main coronary artery percutaneous coronary intervention (PCI)
in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery) trial. Stratiﬁcation across pre-PCI diastolic distal BA
tertiles (<82, 82 to 106, 107) failed to show any difference in major adverse
cardiac and cardiovascular event rates either in all patients eligible for analysis
(n ¼ 266, p ¼ 0.99), or in the ones who underwent bifurcation PCI (n ¼ 185,
p ¼ 0.78). However, a restricted post-procedural systolic-diastolic distal BA range
(<10) resulted in higher major adverse cardiac and cardiovascular event rates
(50.8% vs. 22.7%, p < 0.001) in all patients undergoing bifurcation PCI.EDITORIAL COMMENTLeft Main Percutaneous Coronary Intervention: Growing in Maturity 1261Fausto Feres, Ricardo A. Costa(continued on A-31)
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RESEARCH5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and
TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial (Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the
Treatment of Patients With De Novo Native Coronary Artery Lesions)1263Hemal Gada, Ajay J. Kirtane, William Newman, Mark Sanz, James B. Hermiller,
Kenneth W. Mahaffey, Donald E. Cutlip, Krishnankutty Sudhir, Liming Hou, Kai Koo,
Gregg W. Stone
In order to evaluate long-term safety and efﬁcacy of everolimus-eluting stents (EES)
and paclitaxel-eluting stents (PES), this study examined long-term outcomes of the
SPIRIT III trial. Endpoints included ischemia-driven target vessel failure (TVF)
(the pre-speciﬁed primary endpoint), target lesion failure (TLF), major adverse
cardiac events (MACE) (cardiac death, myocardial infarction, or ischemia-driven
target lesion revascularization), and stent thrombosis. Treatment with EES versus
PES resulted in lower 5-year Kaplan-Meier rates of TVF (19.3% vs. 24.5%,
p ¼ 0.05), TLF (12.7% vs. 19.0%, p ¼ 0.008), and MACE (13.2% vs. 20.7%,
p ¼ 0.007). EES, compared to PES, resulted in durable beneﬁts in safety and
efﬁcacy measures as well as all-cause mortality.
See additional content in the online version of this issue.Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation
Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents:
Results From a Registry of 18,334 Patients1267Tomohisa Tada, Robert A. Byrne, Iva Simunovic, Lamin A. King, Salvatore Cassese,
Michael Joner, Massimiliano Fusaro, Simon Schneider, Stefanie Schulz, Tareq Ibrahim,
Ilka Ott, Steffen Massberg, Karl-Ludwig Laugwitz, Adnan Kastrati
This study compared the risk of stent thrombosis in 18,334 patients undergoing
successful coronary stent implantation from 1998 to 2011 with bare-metal stents
(BMS), ﬁrst-generation drug-eluting stents (G1-DES), and second-generation
drug-eluting stents (G2-DES). The cumulative incidence of deﬁnite stent
thrombosis at 3 years was 1.5% with BMS, 2.2% with G1-DES, and 1.0% with
G2-DES. On multivariate analysis, compared with BMSs, G1-DES, but not
G2-DES, showed a signiﬁcantly higher risk of stent thrombosis. Beyond 1 year, the
risk of stent thrombosis was signiﬁcantly increased with G1-DES compared with
BMS but not with G2-DES.
See additional content in the online version of this issue.(continued on A-32)
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A-32Concomitant Administration of Clopidogrel With Statins or Calcium-Channel
Blockers: Insights From the TRITON–TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibition With
Prasugrel–Thrombolysis In Myocardial Infarction 38)1275Oluseyi Ojeifo, Stephen D. Wiviott, Elliott M. Antman, Sabina A. Murphy, Jacob A. Udell,
Eric R. Bates, Jessica L. Mega, Marc S. Sabatine, Michelle L. O’Donoghue
Concerns have been raised that statins and calcium channel blockers (CCBs) may
attenuate the pharmacodynamic effects of clopidogrel. The TRITON–TIMI 38
trial enrolled acute coronary syndrome patients and randomized them to clopidogrel
or prasugrel. Of the 6,795 subjects assigned to clopidogrel, 4,794 (70.6%) were on
a CYP3A4-metabolized statin, and 966 (14.2%) were on a CCB at randomization.
The risk of cardiovascular death, myocardial infarction, or stroke was similar
regardless of baseline use of statins (adjusted hazard ratio [HR]: 1.02; 95% conﬁ-
dence interval [CI]: 0.85 to 1.22) or CCBs (adjusted HR: 1.16; 95% CI: 0.94 to
1.43) in clopidogrel-treated patients.
See additional content in the online version of this issue.EDITORIAL COMMENTDrug Interactions With Good Old Clopidogrel: Case Closed 1282Freek W. A. VerheugtDrug-Eluting Stents for Revascularization of Infrapopliteal Arteries:
Updated Meta-Analysis of Randomized Trials1284Massimiliano Fusaro, Salvatore Cassese, Gjin Ndrepepa, Gunnar Tepe, Lamin King, Ilka Ott,
Mateja Nerad, Heribert Schunkert, Adnan Kastrati
The clinical impact of drug-eluting stent (DES) placement in patients with
atherosclerotic disease of infrapopliteal arteries remains still uncertain. This study
investigated the outcomes associated with primary DES for disease of infrapopliteal
arteries through a meta-analysis of 5 randomized trials including 611 patients. At
1-year follow-up, primary DES reduces the risk of reintervention and amputation
compared with plain balloon angioplasty or bare-metal stent implantation without
any impact on mortality and Rutherford class.
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A-33Drug-Eluting Balloon in Peripheral Intervention for the Superﬁcial Femoral Artery:
The DEBATE-SFA Randomized Trial (Drug Eluting Balloon in Peripheral Intervention
for the Superﬁcial Femoral Artery)1295Francesco Liistro, Simone Grotti, Italo Porto, Paolo Angioli, Lucia Ricci, Kenneth Ducci,
Giovanni Falsini, Giorgio Ventoruzzo, Filippo Turini, Guido Bellandi, Leonardo Bolognese
Whereas paclitaxel-eluting balloons (PEB) have shown advantage over uncoated
balloons (percutaneous transluminal angioplasty [PTA]) in the treatment of simple
femoropopliteal lesions, it is unknown whether these results are applicable to
complex degrees of femoropopliteal axis atheroma. In patients at risk for restenosis,
the DEBATE-SFA trial compared PEB with conventional PTA, followed by
systematic implantation of a self-expanding nitinol bare-metal stent (BMS)
showing that pre-dilation with PEB angioplasty prior to BMS implantation, as
compared with PTA + BMS, reduces restenosis and target lesion revascularization
at 12-month follow-up. Restenosis reduction is maintained irrespective of lesion
length and recanalization technique.Prevalence and Clinical Implications of Newly Revealed, Asymptomatic Abnormal
Ankle-Brachial Index in Patients With Signiﬁcant Coronary Artery Disease1303Jong-Young Lee, Seung-Whan Lee, Woo Seok Lee, Seungbong Han, Yong Kyu Park,
Chang Hee Kwon, Jeong Yoon Jang, Young-Rak Cho, Gyung-Min Park, Jung-Min Ahn,
Won-Jang Kim, Duk-Woo Park, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee,
Seong-Wook Park, Seung-Jung Park
Among 2,424 patients with at least 1 signiﬁcant stenosis (50%) in a major
epicardial coronary artery, total 385 (15.9%) had abnormal ABI, including 348
(14.4%) with ABI 0.9 and 37 (1.5%) with ABI 1.4. During a median follow-up
of 986 days, the 3-year major adverse event rate was signiﬁcantly higher in patients
with abnormal than normal ABI (15.7% vs. 3.3%, p < 0.001). After multivariate
analysis, abnormal ABI was identiﬁed as one of predictors of primary endpoint
(hazard ratio: 1.87; 95% conﬁdence interval: 1.23 to 2.84; p ¼ 0.004). After
adjustment by propensity score matching, abnormal ABI could predict adverse
clinical events.
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A-34Device Closure of Patent Foramen Ovale Versus Medical Therapy in Cryptogenic
Stroke: A Systematic Review and Meta-Analysis1316Abdur R. Khan, Aref A. Bin Abdulhak, Mujeeb A. Sheikh, Sobia Khan, Patricia J. Erwin,
Imad Tleyjeh, Sadik Khuder, Ehab A. Eltahawy
The optimal strategy for secondary prevention of cryptogenic stroke with a patent
foramen ovale (PFO) is unclear. We performed a meta-analysis of randomized
controlled trials comparing device closure with medical therapy in the prevention of
recurrent neurological events in patients with cryptogenic stroke and PFO. The
results were pooled as per the different patient populations deﬁned in the stud-
iesdintention-to-treat, per-protocol, and as-treated cohorts. Our meta-analysis
suggests that PFO closure is beneﬁcial as compared to medical therapy in the
prevention of recurrent stroke/transient ischemic attack. This meta-analysis helps to
further strengthen the role of device closure in cryptogenic stroke.IMAGES IN
INTERVENTIONFrequency-Domain Optical Coherence Tomography Assessment of Unfavorable
Kissing-Balloon Result in Unprotected Left Main Intervention1324Yusuke Fujino, Guilherme F. Attizzani, Satoko Tahara, Kensuke Takagi, Hiram G. Bezerra,
Sunao Nakamura, Marco A. CostaOptical Coherence Tomography of a Bifurcation Lesion Treated With Bioresorbable
Vascular Scaffolds With the “Mini-Crush” Technique1326Charis Costopoulos, Toru Naganuma, Azeem Latib, Antonio ColomboLETTERS TO
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